Can a cancer drug turn back the clock on aging?

NCT ID NCT05835999

Completed Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether a low dose of everolimus, a drug used in cancer, can safely improve signs of aging in 106 adults aged 55-80 who have insulin resistance or prediabetes. Participants take the drug daily or weekly for 24 weeks, and researchers measure changes in metabolism, heart function, and cognition. A younger group is included for comparison but does not receive the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus
What this could lead to: If successful, this could point toward a drug that slows some aspects of aging and improves metabolic health in older adults.
What could go wrong: This is a small, early-phase trial. The drug may not work as hoped, and everolimus can cause side effects like mouth sores or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING INSULIN RESISTANCE

Contacts and locations

Locations

University of Wisconsin-Madison

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.